West Nile virus disease therapeutics : review of the literature for healthcare providers

Details

• Corporate Authors:
  National Center for Emerging and Zoonotic Infectious Diseases (U.S.)
• Description:
  Revised June 15,2015
  
  No antiviral or adjunctive therapies are approved or recommended for the treatment of West Nile virus (WNV) disease; clinical management is supportive. There are numerous case reports and case series regarding the use of various products (e.g., standard and hyperimmune polyclonal immune globulin, monoclonal immune globulin, interferon, ribavirin, and corticosteroids) in patients with WNV disease. Several of these products have been studied in controlled clinical trials for infections due to WNV or closely related flaviruses (i.e., St. Louis encephalitis and Japanese encephalitis viruses). None have shown benefit. However, the studies often had small sample sizes and the results from some of the clinical trials have not been published. Since polyclonal immune globulin and interferon alpha-n3 are available, some physicians have chosen to use them to treat transplant recipients and other severely immunocompromised patients but there is no proven benefit.
  
  WNV-therapeutics-summary.pdf
  
  
• Subjects:
  West Nile Fever West Nile Fever/prevention & Control
• Document Type:
  Pamphlet (or booklet)
• Genre:
  Fact Sheet
• Pages in Document:
  8 numbered pages
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha256:3182fdfd430cfc602e14a1fda344778ecbd80a53bba024d92567e3c39c9e2067
• Download URL:
  https://stacks.cdc.gov/view/cdc/60297/cdc_60297_DS1.pdf
• File Type:
  [PDF - 200.21 KB ]